bristol myers squibb food and drug administration news - Search News

Bristol Myers Squibb, Schizophrenia

Seeking Alpha · 2h

Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.

Investopedia on MSN · 17h

Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval

Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.

Reuters on MSN · 21h

Bristol Myers wins US FDA approval for new type of schizophrenia drug

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades. The labeling information of the treatment,

Business Wire7h

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

A new kind of drug for schizophrenia promises fewer side effects

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

22h

Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco

Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...

16h

Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns

Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results